Myriad Genetics Teams Up with Lumea for Enhanced Cancer Diagnostics
Myriad Genetics, Inc. (NASDAQ: MYGN), a front-runner in genetic and genomic testing, is thrilled to announce its collaboration with Lumea Inc., a prominent force in digital pathology solutions. The two companies have officially signed an agreement to seamlessly integrate some of the most advanced molecular diagnostic tests, including Prolaris® and MyRisk®, into Lumea’s digital pathology platform known as BxLink™. This collaboration comes with the shared goal of enhancing the security, efficiency, and accessibility of cancer testing for healthcare providers.
The Importance of Streamlined Testing
The integration of Myriad’s Prolaris and MyRisk tests into BxLink is a significant milestone. It will allow healthcare professionals to easily order and track these molecular tests, receiving results directly through the intuitive platform. By automating the testing process, the collaboration aims to minimize manual errors, delivering results in an impressive average turnaround time of under 10 days from specimen collection. This speed is crucial in medical settings where timely information can significantly influence treatment decisions.
Why This Collaboration Matters
Dr. George Daneker, Jr., the President and Chief Clinical Officer of Oncology at Myriad Genetics, emphasized the need for quick access to diagnostic tools. The Prolaris test is vital because it quantifies how aggressive prostate cancer is, guiding doctors on treatment options following a cancer diagnosis. On the other side, MyRisk evaluates up to 48 different genes linked to hereditary cancer risks, providing critical insights for patients and their families. By ensuring these tests are easily accessible, this partnership empowers healthcare providers and patients alike to make well-informed decisions at critical junctures.
Enhancing Clinical Decision-Making
Jim Pack, the CEO of Lumea, expressed that the integration of these tests simplifies clinical workflows significantly. The streamlined process means fewer clicks for clinicians, which leads to reduced data entry errors. As a result, they can more efficiently order tests, access actionable insights from within a trusted platform, and deliver tailored care to patients. This collaboration is designed not just for ease of use but also to uncover new treatment options, encourage participation in clinical trials, and overall, improve patient outcomes.
About the Companies Involved
Lumea: Transforming Pathology
Lumea stands as a leader in clinical digital pathology, boasting a decade of innovative practice and processing a monumental volume of digital diagnoses across the U.S. The company’s technology, combined with AI-driven workflows, sets an unprecedented standard in efficiency and quality. This dedication to patient-centered care has seen its adoption grow to over 50% of the U.S. urology market, extending across five continents and fundamentally transforming cancer diagnostics.
Myriad Genetics: Pioneering Precision Medicine
Myriad Genetics is dedicated to shaping the future of healthcare through genetic testing and precision medicine. By crafting genetically-based tests, Myriad helps identify disease risks and supports informed treatment decisions tailored to individual patient profiles. The information gleaned from these tests serves to enhance patient care and drive down overall healthcare costs. To learn more about their innovations, you can visit their official website.
Frequently Asked Questions
What is the partnership between Myriad Genetics and Lumea about?
This collaboration aims to integrate Myriad Genetics’ molecular diagnostic tests, such as Prolaris and MyRisk, into Lumea’s BxLink platform to streamline cancer testing processes.
How will this collaboration improve cancer testing?
By automating the ordering and tracking of tests, the collaboration aims to deliver results more efficiently, reducing errors and improving the speed at which clinicians receive critical information.
Who are the key figures in this partnership?
Dr. George Daneker, Jr. represents Myriad Genetics as the President and Chief Clinical Officer of Oncology, while Jim Pack serves as the CEO of Lumea.
What are Prolaris and MyRisk tests used for?
Prolaris quantifies the aggressiveness of prostate cancer to guide treatment decisions, while MyRisk evaluates hereditary cancer risks through gene analysis.
What are the benefits of the BxLink platform?
BxLink enhances the workflow for healthcare providers, allowing for easy access to molecular diagnostic results, ultimately leading to better patient outcomes through informed decision-making.
